



DEHP Down-Regulates *Tshr* Gene Expression in Rat Thyroid Tissues and FRTL-5 Rat Thyrocytes: A Potential Mechanism of Thyroid Disruption

Min Joo Kim^{1,2}, Hwan Hee Kim², Young Shin Song³, Ok-Hee Kim⁴, Kyungho Choi⁵, Sujin Kim^{5,6}, Byung-Chul Oh⁴, Young Joo Park^{2,7}

¹Seoul National University Hospital Healthcare System Gangnam Center; ²Department of Internal Medicine, Seoul National University College of Medicine, Seoul; ³Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam; ⁴Department of Physiology, Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon; ⁵Graduate School of Public Health, Seoul National University, Seoul, Korea; ⁶Department of Environmental Science and Institute of Biomedical Studies, Baylor University, Waco, TX, USA; ⁷Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea

Background: Di-2-ethylhexyl phthalate (DEHP) is known to disrupt thyroid hormonal status. However, the underlying molecular mechanism of this disruption is unclear. Therefore, we investigated the direct effects of DEHP on the thyroid gland.

Methods: DEHP (vehicle, 50 mg/kg, and 500 mg/kg) was administered to Sprague-Dawley rats for 2 weeks. The expression of the thyroid hormone synthesis pathway in rat thyroid tissues was analyzed through RNA sequencing analysis, quantitative reverse transcription-polymerase chain reaction (RT-PCR), and immunohistochemical (IHC) staining. DEHP was treated to FRTL-5 rat thyroid cells, and an RT-PCR analysis was performed. A reporter gene assay containing the promoter of thyroid stimulating hormone receptor (*TSHR*) in Nthy-ori 3-1 human thyroid cells was constructed, and luciferase activity was determined.

Results: After DEHP treatment, the free thyroxine (T4) and total T4 levels in rats significantly decreased. RNA sequencing analysis of rat thyroid tissues showed little difference between vehicle and DEHP groups. In the RT-PCR analysis, *Tshr* expression was significantly lower in both DEHP groups (50 and 500 mg/kg) compared to that in the vehicle group, and IHC staining showed that *TSHR* expression in the 50 mg/kg DEHP group significantly decreased. DEHP treatment to FRTL-5 cells significantly down-regulated *Tshr* expression. DEHP treatment also reduced luciferase activity in a reporter gene assay for *TSHR*.

Conclusion: Although overall genetic changes in the thyroid hormone synthesis pathway are not clear, DEHP exposure could significantly down-regulate *Tshr* expression in thyroid glands. Down-regulation of *Tshr* gene appears to be one of potential mechanisms of thyroid disruption by DEHP exposure.

Keywords: Diethylhexyl phthalate; Endocrine disruptors; Thyroid gland; Receptors, thyrotropin

Received: 20 November 2020, Revised: 27 January 2021,

Accepted: 29 January 2021

Corresponding authors: Young Joo Park

Department of Internal Medicine, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea

Tel: +82-2-2072-4183, Fax: +82-2-764-2199, E-mail: yjparkmd@snu.ac.kr

Byung-Chul Oh

Department of Physiology, Lee Gil Ya Cancer and Diabetes Institute, Gachon
University College of Medicine, 155 Gaetbeol-ro Yeonsu-gu, Incheon 21999,
Korea

Tel: +82-32-899-6074, Fax: +82-32-899-6246, E-mail: bcOH@gachon.ac.kr

Copyright © 2021 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Thyroid disrupting chemicals (TDCs) can interfere with the thyroid hormones [1,2]. The thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are essential for the growth and differentiation of various tissues and organs as well as energy homeostasis and metabolic regulation. Because thyroid hormones are critical in neurocognitive development, maternal thyroid dysfunction during early pregnancy can lead to a lower offspring intelligent quotient (IQ) and neurodevelopmental diseases [3,4]. Therefore, TDCs have important implications for human health [5].

Several chemicals, including phthalates, bisphenols, perchlorate, polychlorinated biphenyls, and polybrominated diphenyl ethers, are known as TDCs [1]. TDCs can affect the hypothalamic–pituitary–thyroid (HPT) axis through various mechanisms [1,6]; these include thyroid hormone synthesis by the thyroid gland, regulation by hypothalamic–pituitary hormones, thyroid hormone-binding proteins, cell uptake of thyroid hormones, thyroid hormone metabolism, and excretion by the liver. Although several chemicals have been identified as TDCs, the mechanisms through which they work remain undetermined. In particular, little is known about the direct effect of TDCs on the thyroid gland. When thyroid stimulating hormone (TSH) binds to a TSH receptor (TSHR) in the thyroid cell membrane, the thyroid hormone synthesis pathway is activated; TSH activates iodine uptake and the transcription of sodium iodide symporter (NIS), thyroglobulin (TG), and thyroperoxidase (TPO). Iodine uptake to thyroid follicular cells is a critical initial step for thyroid hormone synthesis and is mediated by NIS. Iodide is then oxidized by TPO and incorporated into the tyrosyl residues of TG. Iodotyrosines are subsequently coupled with TPO to form T4 and T3. Therefore, the inhibitions/blockages of this process can reduce thyroid hormone synthesis.

Di-2-ethylhexyl phthalate (DEHP) is one of the most commonly used phthalates. It acts as a plasticizer and softener in various commercial products, including food packaging, building materials, children's toys, medical devices, and cosmetics. Although DEHP is still in use, its impacts on human health are debated [7]. DEHP can affect thyroid hormones and the HPT axis in humans. A recent meta-analysis of previous research showed that urinary concentrations of mono-(2-ethylhexyl) phthalate (MEHP) and mono (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), which are metabolites of DEHP, were negatively correlated with total T4 [8]. Animal experiments also reported that DEHP exposure reduced total T4 and/or free T4 [9-12].

DEHP exposure to rats changed thyroid histology, including follicular cell hyperplasia and decrease in thyroid follicle size [9,10,12-14]. There are some studies on molecular level change within the thyroid gland, but the results of them are conflicting. Liu et al. [12] reported that high dose (500 to 750 mg/kg) of DEHP for 30 days down-regulated *Tshr* expression in thyroid tissues of rats. However, Sun et al. [15] reported that 500 mg/kg of DEHP increased *Tshr* mRNA expression and decreased TSHR protein expression in rats. However, long-term exposure to high dose (150 to 600 mg/kg) of DEHP for 3 or 6 months increased the expression of TSHR, TG, and TPO in rats [16,17]. Because the results of long-term exposure and *in vivo* experiments may not be a direct effect of DEHP, we conducted an animal experiment with short-term exposure and *in vitro* experiment with FRTL-5 rat thyrocytes. In addition, transcriptome analysis in rat thyroid tissues was performed to check the overall genetic changes at once as the effect of DEHP on the liver using RNA sequencing analysis has been previously reported [18,19].

METHODS

Animals

Sprague-Dawley male rats were purchased from Orientbio (Seongnam, Korea). The rats were maintained at room temperature with a 12-hour light/12-hour dark cycle. The animals were fed with a chow diet (Picolab Rodent Diet 20, Orientbio) and tap water was available *ad libitum*. Rats at 8 weeks of age were divided into three groups ($n=6$ in each group, duplicated): vehicle (corn oil), 50 mg/kg DEHP (Sigma Aldrich, St. Louis, MO, USA), and 500 mg/kg DEHP groups ($n=6$ in each group). The vehicle or DEHP (dissolved in dimethyl sulfoxide [DMSO]) was administered orally by gavage for 2 weeks. All animal experiments were approved by the animal ethics committee of Gachon University, Lee Gil Ya Cancer and Diabetes Institute (LCDI-2016-0079).

Cell cultures

A fresh subclone of FRTL-5 rat thyroid cells was obtained from the Interthyr Research Foundation (Dr. Leonard D. Kohn, Ohio University, Athens, OH, USA). Cells were grown in a 6H medium, consisting of Coon's modified F-12 medium supplemented with 5% calf serum, 1 mM nonessential amino acids, and a mixture of six hormones: bovine TSH (10 U/L), insulin (10 mg/L), hydrocortisone (0.4 mg/L), human transferrin (5 mg/L), glycyl-L-histidyl-L-lysine acetate (10 μ g/L), and somatostatin (10 μ g/L). Various concentrations of DEHP (Sigma Aldrich) were admin-

istered to cells in a 5H medium, which is the same composition with 6H except for TSH, with 0.5% calf serum for 24 hours. DEHP was dissolved in DMSO and then added to culture medium. In the culture media of all groups including the vehicle group, the DMSO concentration was the same as 0.1%.

TSHR luciferase reporter assay

The human *TSHR* gene promoter, as defined by the location corresponding to the transcriptional site, was amplified 1,422 bp with polymerase chain reaction (PCR) using the following primers: forward (5'-AAAGGTACC TTCCATAACAATAC-CATGGT-3') and reverse (5'-AAA CTCGAGTTTCCACG-GGACTCGGGGCT-3') and then cloned into the firefly luciferase reporter vector pGL4.14 (Promega, Madison, WI, USA). Nthy-ori 3-1 cells were seeded in 12-well plates at a density of 8×10^4 cells per well in RPMI1640 medium (Welgene, Seoul, Korea) containing 10% fetal bovine serum 1 day before transfection. After 24 hours, each well was transfected with 200 ng of pGL4.14-hTSHR using 1 μ L of the transfection reagent Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA, USA). Cells were treated with vehicle (dimethyl sulfoxide) or 3 to 100 nM concentrations of DEHP. After a 24-hour incubation, the luciferase activity was determined using the Luciferase assay system (Promega) according to the manufacturer instructions. Luminescence was measured with Lumat LB9507 (Berthod Technologies, Bad Wildbad, Germany). To adjust the transfection efficiency, cytomegalovirus (CMV)- β -gal vector was used and β -gal activity was quantified by spectrophotometer at 420 nm (VersaMax Microplate Reader, Molecular Devices, Silicon Valley, CA, USA).

Thyroid hormone measurements

Blood was drawn through an inferior vena cava puncture, and serum was obtained from centrifugation. Serum TSH concentration was measured using an enzyme-linked immunosorbent assay (ELISA) kit (ALPCO, Salem, NH, USA) following the manufacturer's protocol. Total and free T4 were measured by radioimmunoassay kits (Cisbio Bioassays, Codolet, France and Shin Jin Medics Inc., Goyang, Korea, respectively). Total and free T3 were measured by radioimmunoassay kits (Institute of Isotopes Co. Ltd., Budapest, Hungary and Thermo Fisher Scientific, respectively).

RNA isolation from rat thyroid tissues and RNA sequencing

Total RNA was extracted from rat thyroid tissues using the TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to

the manufacturer's instructions. RNA purity was assessed using a NanoDrop spectrophotometer. RNA sequencing was performed per previously established methods [20]; five of the vehicle group and three of each DEHP group. The normalized gene expression values were applied to principal component analysis (PCA) using the 500 most variable genes. The differentially expressed genes (DEGs) were defined by DESeq2 to have an adjusted *P* value of < 0.05 , $|\log_2(\text{fold change})| \geq 1$, and a base mean ≥ 100 , using normalized raw counts of sequencing reads by the regularized log transformation method [21]. To adjust for the multiple testing of 32,494 genes detected by RNA sequencing, the adjusted *P* value was calculated using the Benjamini-Hochberg correction. To construct a heatmap, the centered rlog values were applied to hierarchical clustering using Cluster 3.0 [22]. Pathway enrichment analysis was conducted to determine biologically significant pathways using overlaps of genes of interest with specific gene sets or pathways using the Kyoto Encyclopedia of Genes and Genomes pathway database [23], and detailed methods were described previously [24].

Quantitative reverse transcription-polymerase chain reactions

After total RNA extraction from rat thyroid tissues or cells, cDNA was synthesized from 1 μ g of total RNA with the moloney murine leukemia virus (M-MLV) reverse transcriptase kit (Invitrogen). Quantitative reverse transcription-polymerase chain reaction (RT-PCR) was performed using the StepOne Plus real-time PCR system (Applied Biosystems, Foster City, CA, USA) with the SYBR Premix Ex Taq polymerase (Takara Bio Inc., Kusatsu, Japan). The PCR primer sets are listed in Supplemental Table S1.

Immunohistochemical staining analysis

Paraffin-embedded thyroid tissues were sectioned to a thickness of 4 μ m. The sections were incubated with primary antibodies for TSHR (goat polyclonal antibody [sc-7816]; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and NIS (rabbit polyclonal antibody [bs-0448R]; Bioss, Beijing, China) overnight at 4°C. After washing, the sections were incubated with secondary anti-goat or anti-rabbit antibody for 1 hour at room temperature and then treated with the Elite ABC kit reagent (Vector Laboratories Ltd., Burlingame, CA, USA) for 30 minutes. For color development, the tissue sections were stained with the 3,3'-diaminobenzidine peroxidase substrate solution (Vector Laboratories Ltd.) and counterstained with Mayer's hematoxylin (Sigma-Aldrich). The sections were examined under a light microscope after

mounting with Permount Mounting Medium (Thermo Fisher Scientific). Immunoreactivity was evaluated semi-quantitatively using Image J software (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis

Data in the figure was presented as a box-and-whisker plot. Serum thyroid hormones and mRNA expression among groups (vehicle and DEHP groups) were compared using one-way analysis of variance (ANOVA) or Kruskal-Wallis test. The statistical analysis was performed using GraphPad Prism version 7.0 software (GraphPad Software Inc., San Diego, CA, USA). $P < 0.05$ was considered to be significant.

RESULTS

Serum thyroid hormones in rats

During DEHP treatment for 2 weeks, there were no overt signs of systemic toxicity in rats. Body weights, liver function, and renal function in DEHP groups were not significantly different from those of the vehicle group (Supplemental Table S2). DEHP treatment significantly reduced free T4 and total T4 (Fig. 1), suggesting thyroid-disruption.

mRNA expressions in rat thyroid tissues

To determine whether the hormonal changes are associated with pathological changes in the thyroid glands, RNA sequencing analysis was performed using thyroid tissues of rats. The PCA analysis showed no different clustering between DEHP and vehicle groups (Fig. 2A). Subsequently, the up-regulated or down-regulated genes in the DEHP groups (50 and 500 mg/kg) compared to the vehicle group were identified (Supplemental Fig.

S1), and the top 10 DEGs were presented in Table 1. However, those genes were not related to thyroid hormone synthesis. The pathway related to thyroid hormone synthesis was not changed, although the pathway enrichment analysis showed changes in some gene sets related to circadian rhythm, oocyte meiosis, and cell cycle (Supplemental Table S3). Next, the expression of individual genes related to thyroid hormone synthesis and thyroid differentiation was analyzed (Fig. 2B). The expressions of *Slc5a5* and *Tpo* in the 500 mg/kg DEHP group were significantly higher than those in the vehicle group (Fig. 2C). The expression of the other genes including *Tshr* was not significantly different between groups.

TSHR expression in rat thyroid tissues

To confirm these results, quantitative RT-PCR analysis with rat thyroid tissues was performed. DEHP treatment significantly decreased *Tshr* mRNA expression in both 50 and 500 mg/kg DEHP groups and increased *Slc5a5* mRNA expression in the 500 mg/kg DEHP group (Fig. 3A). Protein expressions of TSHR and NIS were evaluated using immunohistochemical staining. TSHR expression in the 50 mg/kg DEHP group was significantly decreased compared to that in the vehicle group (Fig. 3B). However, NIS (*Slc5a5*) expression was not different between the DEHP and vehicle groups (Fig. 3C). This suggests that DEHP suppresses TSHR expression but not NIS expression in thyroid glands.

TSHR expression in thyroid cells

To clarify whether DEHP affects thyroid tissues directly, *in vitro* experiments using FRTL-5 rat normal thyrocytes were performed. DEHP treatment above 10 μ M significantly down-regulated *Tshr* expression in a dose-dependent manner (Fig. 4A).




Fig. 1. Serum thyroid hormones in di-2-ethylhexyl phthalate (DEHP)-treated rats. After DEHP treatments (vehicle, 50 mg/kg, or 500 mg/kg DEHP) for 2 weeks, thyroid function test was performed with obtained rat blood ($n=6$ to 12). (A) Free thyroxine (T4), (B) total T4, (C) free triiodothyronine (T3), (D) total T3, (E) thyroid stimulating hormone (TSH). One-way analysis of variance (ANOVA) with Tukey's multiple comparisons test was performed. conc, concentration. ^a $P < 0.05$ compared to the vehicle group.




Fig. 2. mRNA sequencing data of rat thyroid tissues treated with di-2-ethylhexyl phthalate (DEHP) for 2 weeks. (A) Principal component analysis. (B) Heatmap of genes related to thyroid hormone synthesis and thyroid differentiation. (C) Box plots of genes related to thyroid hormone synthesis and thyroid differentiation. PC, principal component.

Table 1. Top 10 Differentially Expressed Genes in Thyroid Tissues of Rats

Down-regulated genes				Up-regulated genes			
Gene	Base mean	Log ₂ fold change	Adjusted P value	Gene	Base mean	Log ₂ fold change	Adjusted P value
<i>Armcx6</i>	238	-0.547	1.29×10 ⁻⁷	<i>Hsph1</i>	1,720	0.769	1.87×10 ⁻⁵
<i>Esy13</i>	481	-0.655	2.69×10 ⁻⁶	<i>Dbp</i>	2,160	0.894	1.87×10 ⁻⁵
<i>Adams4</i>	255	-0.707	1.16×10 ⁻⁴	<i>Per3</i>	899	0.712	1.16×10 ⁻⁴
<i>Arntl</i>	612	-0.731	4.14×10 ⁻⁴	<i>Nr1d1</i>	1,988	0.820	3.14×10 ⁻⁴
<i>Npas2</i>	1,902	-0.674	0.002	<i>Nr1d2</i>	1,493	0.598	3.48×10 ⁻⁴
<i>Tulp1</i>	144	-0.557	0.004	<i>Tef</i>	1,555	0.701	3.80×10 ⁻⁴
<i>Ankrd29.1</i>	516	-0.562	0.005	<i>Pex5l</i>	202	0.720	3.97×10 ⁻⁴
<i>Cyp26b1</i>	241	-0.663	0.007	<i>Gtse1</i>	112	0.735	0.002
<i>Lonrf3</i>	123	-0.608	0.012	<i>Rcc2</i>	955	0.509	0.004
<i>Arhgap20</i>	122	-0.568	0.015	<i>Per2</i>	659	0.634	0.004

Genes in di-2-ethylhexyl phthalate (DEHP) group (50 and 500 mg/kg) were compared with those in the vehicle group.

The *Slc5a5* expression did not show any significant change. Furthermore, the effects of DEHP on the *TSHR* gene were determined using a reporter gene assay in Nthy-ori 3-1 cells. Compared to the vehicle group, DEHP treatment above 10 μM significantly reduced the luciferase activity by 20% (Fig. 4B).

DISCUSSION

DEHP is a well-known TDC, and it can affect thyroid hormone

synthesis. This study demonstrates that DEHP has the potential to decrease thyroid hormone synthesis by inhibiting *Tshr* transcription. DEHP treatment significantly down-regulated the expression of *Tshr* gene both in rat and human thyroid cells. DEHP treatment to rats also reduced TSHR expression.

Epidemiological studies can demonstrate that TDC exposure is associated with decreasing thyroid hormone levels; however, the mechanism through which TDC disrupts thyroid hormones is challenging to examine in humans. Therefore, the mechanism




Fig. 3. Expression of gene related to thyroid hormone synthesis in rat thyroid tissues ($n=6$ to 12) treated with di-2-ethylhexyl phthalate (DEHP) for 2 weeks. (A) Reverse transcription-polymerase chain reaction (RT-PCR) analysis. (B) Representative image of thyroid stimulating hormone receptor (TSHR) immunohistochemical (IHC) staining (1:100) and quantification of TSHR positive area per total area (%). (C) Representative image of sodium iodide symporter (NIS) IHC staining (1:100) and quantification of TSHR positive area per total area (%). One-way analysis of variance (ANOVA) with Tukey's multiple comparisons test was performed. conc, concentration. ^a $P<0.05$; ^b $P<0.01$.




Fig. 4. Expression of gene related to thyroid hormone synthesis in thyroid cells treated with di-2-ethylhexyl phthalate (DEHP). (A) mRNA expression level of genes related to thyroid hormone synthesis (*Tshr*, *Slc5a5*, *Tg*, and *Tpo*) in FRTL-5 cells treated with DEHP for 24 hours. (B) Thyroid stimulating hormone receptor (TSHR) luciferase reporter assay. Luciferase activity in Nthy-ori 3-1 cells treated with DEHP for 24 hours. ^a $P<0.05$; ^b $P<0.01$.

has been studied through animal or cell experiments. In rat experiments, DEHP treatment significantly reduced total T4 and/or free T4 [9-11]. DEHP exposure also induced histological changes of the thyroid glands in rats [9,10,12,13], suggesting a direct effect of DEHP on thyroid hormone synthesis. However, the detailed molecular mechanism of this effect was unclear. In this study, genetic changes were extensively investigated using RNA sequencing; however, the overall change in the thyroid hormone synthesis pathway was not significant. Only decreased *Tshr* expression in DEHP groups were consistently observed in rat thyroid tissues. *In vitro* cell experiments, including a reporter gene assay, also demonstrated that DEHP could directly down-regulate *Tshr* expression in thyrocytes. As TSH is the most important stimulant for thyroid hormone synthesis, a decrease in TSHR can weaken the TSH signal, leading to a reduction in serum thyroid hormone. This study observed that a 500 mg/kg DEHP treatment increased mRNA expression of NIS (*Slc5a5*) in rat thyroid tissues. However, the changes in the protein expression of NIS in rat thyroid tissues were not significant. It has been reported that the treatment of MEHP, a metabolite of DEHP, increased mRNA expression of NIS in zebrafish [25], whereas DEHP treatment did not change protein expressions of NIS in rat thyroid tissues [9]. DEHP treatment to FRTL-5 cells did not increase the mRNA expression of NIS in this study. Therefore, the changes in NIS within thyroid tissues or thyrocytes seem to be secondary or compensatory responses.

Although this study suggested that DEHP has the potential to directly affect the thyroid gland and reduce thyroid hormone synthesis, the impact may be small. RNA sequencing analysis of rat thyroid tissues showed that the overall change in the thyroid hormone synthesis pathway was not significant. Because RNA sequencing analysis was conducted with a small number of samples ($n=3$ to 5), there is a possibility of false negatives. RT-PCR analysis with more number of samples showed that DEHP treatment to rat or thyroid cells down-regulated *Tshr* expression, but the expression of other genes related to thyroid hormone synthesis did not change. This suggests that DEHP disrupts the thyroid hormone system through pathways other than those within the thyroid gland; there are various possible mechanisms that have been reported [1,2]. DEHP exposure to rats altered expressions of thyrotropin-releasing hormone receptor (TRHR) and TSH β in rat hypothalamus/pituitary tissues [9,10,12,15,16]. This suggests that DEHP can affect thyroid hormone regulation through the hypothalamic-pituitary hormone. DEHP exposure to rats or zebrafish decreased transthyretin, a major binding protein that transports thyroid hormones in

blood [9,12]. DEHP exposure to rats or zebrafish altered deiodinase 1 activity and induced UDP-glucuronosyltransferase 1A1 (UGT1A1) and sulfotransferase 1E1 (SULT1E1) in the liver [9,10,12,15,25], hepatic enzymes related to thyroid hormone metabolism. It suggested that DEHP can affect thyroid hormone metabolism, resulting in thyroid hormone changes.

In conclusion, DEHP exposure could down-regulate *Tshr* gene directly in thyroid glands of rats, leading to a decreased thyroid hormone synthesis. Other direct and indirect mechanisms of thyroid hormone disruption in addition to *Tshr* gene down-regulation deserve further investigation.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This study was funded by a grant (18182MFDS365) from Ministry of Food and Drug Safety in 2018.

AUTHOR CONTRIBUTIONS

Conception or design: M.J.K., K.C., S.K., B.C.O., Y.J.P. Acquisition, analysis, or interpretation of data: M.J.K., H.H.K., Y.S.S., O.H.K., B.C.O. Drafting the work or revising: M.J.K., Y.S.S., O.H.K., S.K., B.C.O., Y.J.P. Final approval of the manuscript: M.J.K., H.H.K., Y.S.S., O.H.K., K.C., S.K., B.C.O., Y.J.P.

ORCID

Min Joo Kim <https://orcid.org/0000-0002-9765-9340>

Byung-Chul Oh <https://orcid.org/0000-0002-4277-7083>

Young Joo Park <https://orcid.org/0000-0002-3671-6364>

REFERENCES

1. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. EDC-2: the Endocrine Society's second scientific statement on endocrine-disrupting chemicals. *Endocr Rev* 2015;36:E1-150.
2. Boas M, Feldt-Rasmussen U, Main KM. Thyroid effects of endocrine disrupting chemicals. *Mol Cell Endocrinol* 2012; 355:240-8.
3. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight

- GJ, Gagnon J, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med* 1999;341:549-55.
4. Henrichs J, Bongers-Schokking JJ, Schenk JJ, Ghassabian A, Schmidt HG, Visser TJ, et al. Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study. *J Clin Endocrinol Metab* 2010;95:4227-34.
 5. Mughal BB, Fini JB, Demeneix BA. Thyroid-disrupting chemicals and brain development: an update. *Endocr Connect* 2018;7:R160-86.
 6. Jugan ML, Levi Y, Blondeau JP. Endocrine disruptors and thyroid hormone physiology. *Biochem Pharmacol* 2010;79:939-47.
 7. Miles-Richardson SR, Bosch S, Swarts S, Lladós F, Gray DA. Toxicological profile for di(2-Ethylhexyl)phthalate (DEHP). Atlanta: Department of Health and Human Services; 2002.
 8. Kim MJ, Moon S, Oh BC, Jung D, Choi K, Park YJ. Association between diethylhexyl phthalate exposure and thyroid function: a meta-analysis. *Thyroid* 2019;29:183-92.
 9. Zhang P, Guan X, Yang M, Zeng L, Liu C. Roles and potential mechanisms of selenium in countering thyrotoxicity of DEHP. *Sci Total Environ* 2018;619-620:732-9.
 10. Ye H, Ha M, Yang M, Yue P, Xie Z, Liu C. Di2-ethylhexyl phthalate disrupts thyroid hormone homeostasis through activating the Ras/Akt/TRHr pathway and inducing hepatic enzymes. *Sci Rep* 2017;7:40153.
 11. Yamaguchi T, Maeda M, Ogata K, Abe J, Utsumi T, Kimura K. The effects on the endocrine system under hepatotoxicity induction by phenobarbital and di(2-ethylhexyl)phthalate in intact juvenile male rats. *J Toxicol Sci* 2019;44:459-69.
 12. Liu C, Zhao L, Wei L, Li L. DEHP reduces thyroid hormones via interacting with hormone synthesis-related proteins, deiodinases, transthyretin, receptors, and hepatic enzymes in rats. *Environ Sci Pollut Res Int* 2015;22:12711-9.
 13. Howarth JA, Price SC, Dobrota M, Kentish PA, Hinton RH. Effects on male rats of di-(2-ethylhexyl) phthalate and di-n-hexylphthalate administered alone or in combination. *Toxicol Lett* 2001;121:35-43.
 14. Kim M, Jeong JS, Kim H, Hwang S, Park IH, Lee BC, et al. Low dose exposure to di-2-ethylhexylphthalate in juvenile rats alters the expression of genes related with thyroid hormone regulation. *Biomol Ther (Seoul)* 2018;26:512-9.
 15. Sun D, Zhou L, Wang S, Liu T, Zhu J, Jia Y, et al. Effect of di-(2-ethylhexyl) phthalate on the hypothalamus-pituitary-thyroid axis in adolescent rat. *Endocr J* 2018;65:261-8.
 16. Dong X, Dong J, Zhao Y, Guo J, Wang Z, Liu M, et al. Effects of long-term in vivo exposure to di-2-ethylhexylphthalate on thyroid hormones and the TSH/TSHR signaling pathways in Wistar rats. *Int J Environ Res Public Health* 2017;14:44.
 17. Kim S, Park GY, Yoo YJ, Jeong JS, Nam KT, Jee SH, et al. Di-2-ethylhexylphthalate promotes thyroid cell proliferation and DNA damage through activating thyrotropin-receptor-mediated pathways in vitro and in vivo. *Food Chem Toxicol* 2019;124:265-72.
 18. Zhang L, Hu Y, Sun W, Chen S, Jia X, Cai W. Transcriptomic responses of Nile tilapia (*Oreochromis niloticus*) liver to environmental concentration of di(2-ethylhexyl)phthalate. *Ecotoxicol Environ Saf* 2018;165:70-7.
 19. Huff M, da Silveira WA, Carnevali O, Renaud L, Hardiman G. Systems analysis of the liver transcriptome in adult male zebrafish exposed to the plasticizer (2-ethylhexyl) phthalate (DEHP). *Sci Rep* 2018;8:2118.
 20. Yoo SK, Lee S, Kim SJ, Jee HG, Kim BA, Cho H, et al. Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers. *PLoS Genet* 2016;12:e1006239.
 21. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
 22. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. *Bioinformatics* 2004;20:1453-4.
 23. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res* 1999;27:29-34.
 24. Cho BA, Yoo SK, Song YS, Kim SJ, Lee KE, Shong M, et al. Transcriptome network analysis reveals aging-related mitochondrial and proteasomal dysfunction and immune activation in human thyroid. *Thyroid* 2018;28:656-66.
 25. Zhai W, Huang Z, Chen L, Feng C, Li B, Li T. Thyroid endocrine disruption in zebrafish larvae after exposure to mono-(2-ethylhexyl) phthalate (MEHP). *PLoS One* 2014;9:e92465.